Martin H. Huber Jr. - 15 Jun 2022 Form 4/A - Amendment Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: PRESIDENT AND HEAD OF R&D
Signature: /s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol: XLO
Transactions as of: 15 Jun 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 23 Jun 2022, 19:30:17 UTC
Date Of Original Report: 17 Jun 2022
Previous filing: 10 Jun 2022
Next filing: 04 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLO	Stock Option (right to buy)	Award	$0	+20,000		$0.000000	20,000	15 Jun 2022	Common Stock	20,000	$2.28	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option award was granted on June 15, 2022 and shall vest on July 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until June 1, 2026.

Remarks:

This amendment is being filed solely to correct the vesting schedule reported in the original Form 4 filed on June 17, 2022. All other information reported in the original Form 4 remains the same.